How A Wall Street Analyst Started A $4 Billion Obesity Drug Company
Short excerpt below. Click through to read at the original source.
Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it’s now a prime M&A target for giants jostling for their share of a potential $100 billion market.